Exploring biomarkers in neurological diseases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the role of biomarkers in diagnosing and predicting outcomes in patients with neurological diseases. Utilizing advanced omics technologies, including proteomics and metabolomics, researchers will analyze brain tissue, plasma, and cerebrospinal fluid (CSF) samples to identify potential biomarkers. The goal is to enhance understanding of the pathogenesis and facilitate early diagnosis of neurological conditions. The research aims to address key challenges in the identification and characterization of biomarkers in both healthy individuals and patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients with neurological diseases;
2. Subjects or legal agents agree to participate in the study and sign the informed consent.

Exclusion Criteria:

1. Participating in other clinical investigators;
2. Unwilling to be followed up or poor treatment compliance;
3. Other conditions considered unsuitable for inclusion by the researchers.

Where it's running

• First Hospital of Jilin University
  Changchun, Jilin, China Recruiting

Study contacts

• Study coordinator: Yi YY Yang, Ph.D.
• Email: doctoryangyi@163.com
• Phone: 18186872986

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Retroperitoneal Tumor Registry

  This observational registry collects real-world data from people with retroperitoneal tumors to help understand features, treatments, and long-term outcomes.

  Recruiting The First Hospital of Jilin University · Changchun, Jilin · NCT07915895

• Polatuzumab Vedotin plus Rituximab with Reduced-dose chemo for frail seniors with DLBCL

  This trial tests whether a gentler, first-line treatment (Polatuzumab Vedotin with Rituximab and reduced-dose chemo) helps older, frail patients with DLBCL stay disease-free longer.

  Recruiting Phase 4 The First Hospital of Jilin University · Changchun, Jilin · NCT07908888

• Vision-language AI helps emergency CT readers spot thoraco-abdominal problems

  This trial tests whether a self-developed AI model can help radiologists find acute thoraco-abdominal emergencies on CT scans more accurately than standard reading in adult emergency patients.

  Recruiting The First Hospital of Jilin University · Changchun, Jilin · NCT07899931

• Tegileridine for pain after bariatric surgery

  This phase 3 trial tests tegileridine vs standard opioid medicine to see if it provides good pain relief after bariatric surgery while considering sleep apnea status.

  Recruiting Phase 3 The First Hospital of Jilin University · Changchun, Jilin · NCT07844512

• Modular robotic surgery to remove GEJ cancers at Siewert II/III

  This trial tests a modular robotic system to perform minimally invasive removal of Siewert type II/III gastroesophageal junction cancers in adults.

  Recruiting The First Hospital of Jilin University · Changchun, Jilin · NCT07790809

• Removing enlarged cardiophrenic lymph nodes during surgery for advanced ovarian cancer

  This will try removing enlarged cardiophrenic lymph nodes during surgery in women with advanced ovarian, fallopian tube, or primary peritoneal cancer to see if it delays cancer coming back and is safe.

  Recruiting The First Hospital of Jilin University · Changchun, Jilin · NCT07572409

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.